ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York
|
|
- Cameron Jenkins
- 5 years ago
- Views:
Transcription
1 ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York
2 THE FUTURE OF ANTIEMETICS Fausto Roila Medical Oncology, Terni, Italy
3 Steven Grunberg ( )
4 DISCLOSURES: A 30 Year Perspective Research support, consultancy or honoraria: Abeille AH Robbins American Cancer Society American Home Products Aventis Beecham BMS Eisai Eli Lilly Glaxo Glaxo Wellcome GSK Helsinn HMR Lauder Foundation Merrill Dow Marion Merrill Dow Merck MGI National Cancer Institute Pfizer Rhone Poulenc Roche RPR Sancuso Sandoz Sanofi Sanofi-Aventis Schering Plough Smith Kline Beecham Solvay Takeda Tesoro Wyeth No employment, stock or other ownership
5 THE MULTIPLE ROLES FOR SUPPORTIVE CARE IN CANCER Enhance the use of the most effective anti-neoplastic agents Reduce or eliminate associated symptoms and side-effects Preserve or improve quality of life Permit safe out-patient treatment
6 How can we identify targets*? Expression Possible target Expression + activation Promising target Expression + activation + mechanism A major target for a clinical trial Expression + activation + mechanism + drug A potentially valuable therapy * J Fletcher. Sarcoma State of the Science Meeting, June 2002, Bethesda, MD
7 Chemotherapy-induced nausea and vomiting (CINV): Impact on Quality of Life Before chemotherapy (day 1) After chemotherapy (day 3) (N=122) Mean FLIE scores * Patients experiencing CINV Patients without CINV * p=0.001 Functional Living Index Emesis (FLIE): Adapted from CM Lindley et al. Qual Life Res. 1992;1: ; used with permission from Kluwer Academic Publishers 1992.
8 ISSUES IN THE CONTROL OF EMESIS FUTURE AND RESEARCH Complete elimination of vomiting and nausea ENHANCING EMETIC CONTROL IN PRACTICE The Role of Corticosteroids The Choice of Serotonin Antagonist The Use of NK1 Antagonists THE ROLE AND VALUE OF GUIDELINES
9 ISSUES IN THE CONTROL OF EMESIS FUTURE AND RESEARCH Complete elimination of vomiting and nausea ENHANCING EMETIC CONTROL IN PRACTICE The Role of Corticosteroids The Choice of Serotonin Antagonist The Use of NK1 Antagonists THE ROLE AND VALUE OF GUIDELINES
10 THE EFFECT OF ADDING DEXAMETHASONE TO 5-HT 3 ANTAGONISTS ON ACUTE EMESIS Jantunen et al, Eur J Cancer 1997; 33: 66
11 RANDOMIZED TRIAL TESTING DEXAMETHASONE IN DELAYED EMESIS: CTX / ANTHRA (Aapro, Ann Oncol 2010) DAY 1: All patients: Palonosetron 0.25 mg IV + Dexamethasone 8 mg IV RANDOMIZE DAYS 2 & 3: N = 151 n = 149 PLACEBO DEX 4 mg orally 2x / day 5 DAY CR: 54% p = % ACUTE: 70% 69% DELAYED: 62% 66% All women: met breast ca; med age 52. ENDPOINT: 5 DAY CR Noninferior < 15% No nausea (delayed) favored DEX (62% vs 55%); no diff in FLIE (p=0.64) or side effects
12 Aprepitant versus dexamethasone for preventing delayed emesis induced by anthracyclines+ cyclophosphamide chemotherapy in breast cancer patients: a double-blind, multicenter, randomized study Roila F, et al. J Clin Oncol 2013; 31: 603s, abstr. 9614
13 ISSUES IN THE CONTROL OF EMESIS FUTURE AND RESEARCH Complete elimination of vomiting and nausea ENHANCING EMETIC CONTROL IN PRACTICE The Role of Corticosteroids The Choice of Serotonin Antagonist The Use of NK1 Antagonists THE ROLE AND VALUE OF GUIDELINES
14 Binding Affinity of 5-HT 3 Receptor Antagonists 5-HT 3 Antagonist: pk i (nm): Granisetron Ondansetron Dolasetron Van Wijngaarden I et al. Eur J Pharm Mol Pharmacol. 1990;188: Miller RC et al. Drug Dev Res. 1993;28:87 93.
15 SINGLE DOSE 5-HT 3 ANTAGONIST STUDIES - Randomized Comparison Trial (N = 973): Cisplatin 50 mg / M Acute Emesis Ondansetron + Dex Granisetron + Dex For acute emesis: Dexamethasone 20 mg IV; Ondansetron 8 mg IV, Granisetron 3 mg IV Ref: Roila IGAR, Proc ASCO 1995, Ann Oncol 1996
16 ASCO Practice Guideline Update: 2011 Ondansetron may increase the risk of developing abnormal changes in the electrical activity of the heart, which can result in a potentially fatal abnormal heart rhythm Please visit the FDA website for additional information. Reference: Basch et al. J Clin Oncol 29: , 2011
17 Binding Affinity of 5-HT 3 Receptor Antagonists 5-HT 3 Antagonist: pk i (nm): Palonosetron Granisetron Ondansetron Dolasetron Wong EH et al. Br J Pharmacol. 1995;114: Van Wijngaarden I et al. Eur J Pharm Mol Pharmacol. 1990;188: Miller RC et al. Drug Dev Res. 1993;28:87 93.
18 PALONOSETRON EFFICACY: TWO RANDOMIZED TRIALS - Moderately Emetic Chemotherapy (n = 754) - Complete Response (%) * * Palonosetron 0.25 mg Ondansetron/dolasetron * p h h Rubenstein E. Proc ASCO (approved palonosetron dose shown, 3-arm trials, 754 of 1132 patients )
19 RANDOMIZED-DOUBLE BLIND TRIAL COMPARING: PALONOSETRON + DEX versus GRANISETRON + DEX in EITHER CISPLATIN OR AC / EC (N = 1114) R a n d o m i Z e Palonosetron 0.75 mg IV + Dexamethasone 16 mg IV - Versus - Granisetron 40 ug / kg IV + Dexamethasone 16 mg IV Delayed emesis: Dexamethasone days 2 & 3: 8mg IV (Cisplatin), 4 mg PO (AC / EC) Reference: Saito et al. Lancet Oncol, 10; , 2009
20 RANDOMIZED-DOUBLE BLIND TRIAL COMPARING: PALONOSETRON + DEX versus GRANISETRON + DEX in EITHER CISPLATIN OR AC / EC (N = 1114) Complete Control: Palonosetron 0.75mg + Dexamethasone Granisetron 40ug/kg + Dexamethasone 100% - NS p = p = % - 50% % 73.3% 56.8% 44.5% 51.5% 40.4% 25% - ACUTE DELAYED OVERALL Reference: Saito et al. Lancet Oncol, 10; , 2009 Dex: 16mg IV day 1, then 8mg IV (Cis) / 4mg PO (AC) days 2 & 3
21 PALONOSETRON + DEX + APREPITANT versus GRANISETRON + DEX + APREPITANT WITH CISPLATIN (N = 842) Complete Response: 100% - 75% - Palonosetron + Dex + Aprep Granisetron NS p = 0.01 p = % 91.8% 67.2.% 59.1% 65.7% 59.1% + Dex + Aprep 50% - 25% - ACUTE DELAYED OVERALL Reference: Hashimoto et al. Proc ASCO, 2013 abstract #9621
22 RISK FACTORS FOR EMESIS AND CONTROL - Clinical Factors and Personalization - Chemotherapy Regimen Gender Age Chronic Alcohol Intake History
23 EMETIC CONTROL: MOLECULAR STUDIES - Effect of Deletion Variant of the 5-HT 3B Gene on Emetic Response - Number of Emetic Episodes * wt / wt wt / del del / del -100_-102AAG Deletion Variant Genotype * Number of episodes over 24 hours Tremblay et al, J Clin Oncol 21: 2147, 2003
24 NEUROTRANSMITTERS AND EMESIS Dopamine/ DA RAs Histamine Serotonin/ 5-HT 3 RAs Substance P/ NK-1 RAs Emetic reflex Endorphins Acetylcholine GABA Cannabinoids DA = dopamine; GABA = gamma-aminobutyric acid; NK = neurokinin; RAs = receptor antagonists
25 Aprepitant Blocks Brain NK 1 Receptors in Humans Binding of PET tracer to NK 1 receptors prior to aprepitant dosing Blockade of NK 1 receptors after aprepitant dosing Tracer Binding Low High Hargreaves R. J Clin Psychiatry 2002; 63( Suppl.1):
26 Aprepitant Blocks Brain NK 1 Receptors in Humans Binding of PET tracer to NK 1 receptors prior to aprepitant dosing Blockade of NK 1 receptors after aprepitant dosing Low Tracer Binding Brain NK 1 Receptor Occupancy (%) Mean (± SD) Plasma Trough Concentrations of the Aprepitant 3-Day Regimen Aprepitant Plasma Trough Concentration (ng/ml) High Hargreaves R. J Clin Psychiatry 2002; 63( Suppl.1):
27 Aprepitant randomized trials: The role of aprepitant addition in patients receiving cisplatin R A N D O M I S E Ondansetron32 mg IV * + Dexamethasone 20 mg po (then 8 mg bid x 3 days) vs. Ondansetron32 mg IV * + Dexamethasone 12 mg po (then 8 mg bid x 3 days) + Aprepitant 125 mg po (then 80 mg po x 2 days) Heskethet al. J ClinOncol2003; Poli-Bigelli, et al. Cancer2003. * NOTE: 32 mg is NO longer an approved Ondansetron dose
28 Phase III combined data from both Phase III trials: Complete response: high risk chemotherapy (Cisplatin) Acute Emesis Delayed Emesis Aprepitant regimen Ondansetron + Dex % p< % % p< % N= N= Hesketh et al. J Clin Oncol 2003; Poli-Bigelli, et al. Cancer 2003.
29 Phase III combined data from both Phase III trials: Complete response: high risk chemotherapy (Cisplatin) Acute Emesis Delayed Emesis Aprepitant regimen Ondansetron + Dex p< % 73% % p< % N= N= Hesketh et al. J Clin Oncol 2003; Poli-Bigelli, et al. Cancer 2003.
30 TESTING THE ADDITION OF APREPITANT IN A 5-DAY CISPLATIN TRIAL (GERM CELL) Aprepitant 125 mg Day 3, then 80 mg Days HT 3 on Days 1-5 R a n d o m i Z e Dexamethasone 20mg Days 1+2, 4mg bid days 6-7 Placebo Day 1, then days HT 3 on Days 1-5 With Crossover On 2 nd Cycle Dexamethasone 20mg Days 1+2, 4mg bid days 6-7 PATIENTS: 69 men, Median age 32. BEP Chemo 93% (no prior in 83%) Albany C, et al. J Clin Oncol 2012; 30:
31 TESTING THE ADDITION OF APREPITANT IN A 5-DAY CISPLATIN TRIAL (GERM CELL) APREPITANT PLACEBO P NO EMESIS: DAYS % 52% < DAYS % 78% < COMPLETE RESPONSE: DAYS % 15% < DAYS % 35% < DAYS % 13% < Albany C, et al. JCO 2012; Preference strongly favored Aprepitant
32 Aprepitant versus dexamethasone for preventing delayed emesis induced by anthracyclines+ cyclophosphamide chemotherapy in breast cancer patients: a double-blind, multicenter, randomized study Roila F, et al. J Clin Oncol 2013; 31: 603s, abstr. 9614
33 METHODS - A randomized double-blind study comparing aprepitant versus dexamethasone was carried out in naive breast cancer patients treated with anthracyclines + cyclophosphamide - Before chemotherapy, all patients were treated with intravenous palonosetron 0.25 mg and dexamethasone 8 mg plus oral aprepitant 125 mg - On days 2 and 3 patients randomly received oral dexamethasone 4 mg bid or aprepitant 80 mg qd Primary endpoint was rate of complete response (no vomiting, no rescue treatment) from days 2-5 after chemotherapy
34 RESULTS IN THE ACUTE PHASE (551 PTS) Dexamethasone Aprepitant No. of patients (%) 273 (%) 278 (%) RESPONSES complete response 239 (87.6) 236 (84.9) complete protection 179 (65.6) 170 (61.2) total protection 142 (52.0) 147 (52.9) no vomiting 253 (92.7) 251 (90.3) no nausea 142 (52.0) 149 (53.6) no significant nausea (VAS < 25 mm) 84 (30.8) 77 (27.7) mean number of emetic episodes (sd)* 3.8 (3.3) 5.7 (3.2) mean maximum severity of nausea (sd) 39.7 (24.6) 48.7 (26.6) mean duration of nausea, hours (sd) 4.9 (5.8) 6.0 (6.5) *evaluated in patients who vomited; evaluated in patients who had nausea; sd = standard deviation; Complete Response: No vomiting, no rescue treatment; Complete Protection = No vomiting, no rescue treatment, no significant nausea (VAS < 25 mm); Total Protection = No vomiting, no nausea.
35 RESULTS IN THE DELAYED PHASE (551 PTS) Dexameth. Aprepit. P Value No. of patients (%) 273 (%) 278 (%) Complete response 217 (79.5) 221 (79.5) n.s. Complete protection 164 (60.1) 152 (54.7) n.s. Total control 131 (48.0) 120 (43.2) n.s. No vomiting 250 (91.6) 248 (89.2) n.s. No nausea 134 (49.1) 122 (43.9) n.s. No significant nausea 174 (63.7) 158 (56.8) n.s. Mean number of emetic episodes (sd)* 5.7 (6.5) 9.2 (9.4) n.s. Mean maximum severity of nausea (sd) 42.8 (25.9) 45.5 (24.1) n.s. Mean duration of nausea, hours (sd) 14.1 (18.4) 16.6 (21.4) n.s. * in patients who had delayed vomiting (dexamethasone: 23 patients; aprepitant: 30 patients) in patients suffering from delayed nausea (dexamethasone: 139 patients; aprepitant: 156 patients)
36 ADVERSE EVENTS IN DELAYED PHASE Dexamethasone Aprepitant P Value No. of patients (%) 273 (%) 278 (%) Headache 55 (20.1) 49 (17.6) n.s. Diarrhea 2 (0.7) 5 (1.8) n.s. Constipation 52 (19.1) 40 (14.4) n.s. Hiccup 4 (1.5) 6 (2.2) n.s. Asthenia 90 (33.0) 98 (35.3) n.s. Epigastric pain 37 (13.6) 24 (8.6) n.s. Sedation 13 (4.7) 23 (8.3) n.s. Tremors 6 (2.2) 4 (1.4) n.s. Insomnia 8 (2.9) 1 (0.4) 0.02 Agitation 7 (2.6) 8 (2.9) n.s. Face erythema 34 (12.5) 23 (8.3) n.s. Heartburn 22 (8.1) 10 (3.6) 0.03 Anorexia 8 (2.9) 18 (6.5) n.s. Sweating 7 (2.6) 3 (1.1) n.s. Hyperglicemia 2 (0.7) 1 (0.4) n.s. Tachycardia 9 (3.3) 6 (2.2) n.s.
37 ANTIEMETIC TREATMENT Goals with Chemotherapy: All Major Guideline Groups The Strategy is to Prevent Nausea and Vomiting, rather than Treat Complete control in all settings No side-effects Convenient and easy to use
38 NK 1 RECEPTOR ANTAGONIST AGENTS Approved or Under Investigation for Use as Antiemetics Aprepitant (oral) Fos-aprepitant (IV) Netupitant * (and NEPA) * Rolapitant * * Agents under investigation
39 NEPA Clinical Trials Presented in 2013 MEETINGS: ASCO ECCO MASCC SABC ASH PRESENTERS: Aapro Gralla Hesketh Jordan Rugo Schwartzberg
40 NEPA RANDOMIZED PHASE II TRIAL TO ESTABLISH THE NETUPITANT DOSE FOR PHASE III STUDIES Eligibility: No prior chemotherapy Karnofsky Performance Status 70% First course of cisplatin ( 50 mg/m 2 ), with or without other chemotherapy Subjects Enrolled: 694 patients were randomized 677 (98%) received study treatment and the protocol-required Highly Emetic Chemotherapy
41 Treatment Schema: Group Day 1 Days 2 and 3 Day 4 PALO PALO 0.5 mg + DEX 20 mg + Placebo DEX 8 mg BID DEX 8 mg BID NEPA 100 NETU 100 mg + PALO 0.5 mg + DEX 12 mg DEX 4 mg BID DEX 4 mg BID NEPA 200 NETU 200 mg + PALO 0.5 mg + DEX 12 mg DEX 4 mg BID DEX 4 mg BID NEPA 300 NETU 300 mg + PALO 0.5 mg + DEX 12 mg DEX 4 mg BID DEX 4 mg BID APR + OND APR 125 mg + OND 32 mg + DEX 12 mg APR 80 mg + DEX 4 mg BID DEX 4 mg BID PALO = palonosetron, NEPA = fixed dose combination of PALO + netupitant, APR = aprepitant, DEX = dexamethasone, OND = ondansetron. PALO, NEPA, APR, DEX were oral; OND was IV PALO, NEPA and APR administered 60 min prior to HEC Day 1; APR in morning on Days 2-3 OND was 50 ml IV infusion 15 min duration prior to HEC DEX administered 30 min prior to HEC Day 1 then in the morning and evening on days 2-4
42 Complete Response Rates: Overall (0-120h hr) P = P = P = P = PALO NEPA 100 NEPA 200 NEPA 300 APR+OND *p value from logistic regression vs PALO ** p value from a post-hoc logistic regression analysis vs PALO
43 Complete Response Rates: Acute (0-24 hr) and Delayed ( hr) % Patients p-value PALO (N = 136) NEPA 100 (N = 135) NEPA 200 (N = 137) NEPA 300 (N = 135) Acute (0-24 hr) 89.7% 93.3% % % Delayed ( hr) 80.1% 90.4% % % p value from logistic regression vs PALO
44 No Significant Nausea (Maximum VAS < 25 mm) (Acute, Delayed, and Overall) PALO NEPA 100 NEPA 200 NEPA 300 * P 0.05 compared with PALO; not adjusted for multiple comparisons
45 NEPA PHASE III TRIAL IN AC CHEMO Study Design Phase III, multinational, randomized, double-blind study in chemotherapy-naïve patients undergoing Anthracycline - CTX chemo Patients randomized to receive one of the following regimens, on Day 1 only (no continued steroids): N = 1455 Randomized 1:1 Oral NEPA + Oral DEX 12 mg (NEPA = NETU 300 mg + PALO 0.50 mg) Oral PALO 0.50 mg + Oral DEX 20 mg NEPA (netupitant + palo) or PALO were administered 60 minutes prior to chemotherapy; DEX was given orally at 30 minutes prior to chemotherapy No other antiemetic was given as part of either study regimen after Day 1
46 NEPA PHASE III TRIAL IN AC CHEMO Complete Response Rates P = P = P = Percent of patients CR: no emesis, no rescue medication Based on full analysis set of 1449 patients
47 Overview of Treatment Emergent Adverse Events and Most Common ( 2% Incidence) Treatment-Related Adverse Events Adverse Event NEPA + DEX (N = 725) Palonosetron + DEX (N = 725) Patients with at least one treatment emergent Adverse Event 551 (76%) 507 (69.9%) Patients with any treatmentrelated Adverse Event 59 (8.1%) 52 (7.2%) Headache Constipation 24 (3.3%) 15 (2.1%) 22 (3.0%) 15 (2.1%)
48 MULTI-CYCLE NEPA RANDOMIZED TRIAL Phase III, multicenter, multinational, randomized, active controlled, double-blind, double-dummy, parallel group study Patients had not received prior chemotherapy Patients received Highly ( HEC ) or Moderately Emetic Chemo ( MEC ) Group Day 1 Days 2 and 3 Day 4 N = 413 Randomized 3:1 NEPA NEPA (NETU 300 mg + PALO 0.5 mg) + DEX 12 mg (HEC & MEC) HEC: DEX 8 mg MEC: none HEC: DEX 8 mg MEC: none 75/25 % MEC/HEC APR + PALO APR 125 mg + PALO 0.5 mg + DEX 12 mg (HEC & MEC) HEC: APR 80 mg + DEX 8 mg MEC: APR 80 mg HEC: DEX 8 mg MEC: none NEPA, PALO, APR, DEX were all oral Day 1: NEPA and APR administered 60 min prior to chemotherapy, Dexamethasone (DEX) administered 30 min prior to CT
49 Complete Response Rates: Overall (0-120 hr) Over 6 Cycles Percent of patients (%) NEPA N = APR + PALO N = Similar results observed for both the HEC and MEC subsets No formal statistical comparisons were performed
50 NEPA CONCLUSIONS FROM RANDOMIZED TRIALS Netupitant at 300 mg is an appropriate NK 1 RA to add to palonosetron in an all oral combination. This dose was associated with few side effects and high efficacy The addition of netupitant significantly improves the efficacy of palonosetron NEPA as a single dose regimen given only prior to chemotherapy (with dexamethasone on day 1) is effective: In patients receiving Anthracycline + Cyclophosphamide / Moderately Emetic Chemotherapy (MEC) as for breast cancer and requires no further antiemetic agents after day 1 In patients receiving Highly Emetic Chemotherapy (HEC), such as cisplatin, with only dexamethasone continued after day 1 NEPA has few side effects and maintains efficacy over repeated cycles of chemo NEPA provides a straight-forward strategy to enhance the use of guideline-based antiemetic regimens and is maximally convenient to improve patient adherence
51 THREE-DRUG PHASE II TRIAL SINGLE DAY* - Palonosetron + Aprepitant + Dexamethasone (N = 41) - Single Dose Regimen Only (All given once shortly before Chemotherapy): Palonosetron 0.25 mg IV Dexamethasone 20 mg PO Aprepitant 285 mg PO Women: 98% No Prior Chemo: 100% Median Age: 51 Anthracycline + CTX: 95% Acute Emesis Delayed Emesis Overall (5 days) No Nausea or Mild** 78% 68% 66% No Emesis 100% 95% 95% ** Nausea < 26 on a VAS Grunberg et al. Supportive Care in Cancer 2009 * Preliminary Investigative Trial
52 Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III study Navari RM, et al. J Support Oncol 2011; 9:
53 DESIGN OF THE STUDY (241 pts) g. 1 g. 2 g. 3 g. 4 Aprepitant po 125 mg 80 mg 80 mg - Palonosetron iv 0.25 mg Dexamethasone 12 mg 4mg bid 4mg bid 4mg bid Olanzapine po 10 mg 10 mg 10 mg 10 mg Palonosetron iv 0.25 mg Dexamethasone 20 mg dexamethasone iv on day 1 and orally on day 2-4
54 RESULTS (% COMPLETE RESPONSES) OPD APD p Day n.s. Day n.s. Day n.s.
55 It is an open study SHORTCOMINGS Due to the small sample size, the study was only powered to investigate large differences such as a 15% difference in complete response on day 1-5. It was not stated if the study was designed as a superiority, non inferiority or equivalence study. An unplanned interim analysis was carried out but the significance level was not modified according to Bonferroni s inequality.
56 MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Third Major Guideline Update by MASCC over a 15 Year Period Recommendations: Published Ann Oncol 2010 and with periodic web updates the latest in April 2013
57 GUIDELINES AND EVIDENCE-BASED MEDICINE Approaches in Guideline Development Evidence - based Opinion (Consensus) - based Economically - based
58 SUMMARY ACUTE NAUSEA AND VOMITING EMETIC RISK GROUP High Anthracycline + Cyclophosphamide (AC) Moderate (other than AC) ANTIEMETICS HT3 DEX APR or FOS 5HT3 DEX APR 5HT3 DEX APR or FOS DEX 5HT3 DEX APR PALO Low PALO DEX OR + DEX 5HT3 OR DRA Minimal No routine DEXprophylaxis 5HT3 = serotonin receptor antagonist DEX = DEXAMETHASONE APR = APREPITANT; FOS= FOSAPREPITANT PALO = PALONOSETRON DRA = dopamine receptor antagonist * NOTE: If the NK1 receptor antagonist is not available for AC chemotherapy, palonosetron is the preferred 5-HT3 receptor antagonist. The Antiemetic Subcommittee of The Multinational Association of Supportive Care in Cancer. - Ann Oncol 2010; Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide.
59 SUMMARY DELAYED NAUSEA AND VOMITING EMETIC RISK GROUP ANTIEMETICS High DEX* + APR* 5HT3 + DEX + APR Anthracycline + APR or none** Cyclophosphamide (AC) 5HT3 DEX APR Moderate (other than AC) Low Minimal PALO + + DEX + DEX No routine prophylaxis DEX No routine prophylaxis DEX = DEXAMETHASONE APR= APREPITANT The Antiemetic Subcommittee of The Multinational Association of Supportive Care in Cancer. Ann Oncol 2010; Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide.
60 Reported and Actual Application of National and International Antiemetic Guidelines Percentage of European and US Oncologists reporting that they frequently or always use major national or international antiemetic guidelines: 50% 70% Percentage of patients receiving highly or moderately emetic chemotherapy actually given guideline consistent antiemetics in a 991 patient observational study: 29% Aapro, Molassiotis, Dicato et al Proc MASCC 2011
61 Pan European Emesis Registry ( PEER ) Study Design Primary Objective: To compare Complete Response rates over 5 Days postchemotherapy among patients receiving: Guideline consistent Antiemetic prophylaxis (GCCP) with those receiving: Guideline inconsistent Antiemetic prophylaxis (GICP) Aapro, Molassiotis, Dicato et al Proc MASCC 2011
62 Complete Response, 5 Days (cycle 1): PEER Study P= % 71.4% P= % 69.2% GCCP 70% 65% 60% 55% 50% 54.2% 48.9% P= % P= % 59.9% 50.7% GICP 45% 40% 35% 30% HEC (N=189) Female AC (N=463) MEC (N=339) Overall (N = 991) P-values are derived from multivariate model
63 Resource Utilization (cycle 1): PEER Study All Antiemetic Risk Groups Parameter Visit to: Primary Care Physician, or Specialist, or ER GCCP ( Compliant ) ( N = 287 ) GICP ( Not Compliant ) ( N = 704 ) Total ( N = 991 ) N Percent N Percent N Percent % % Hospital days Note: In a busy practice treating 100 patients per day, the rate with non-compliance with Antiemetic Guidelines results in 700 additional urgent visits per year
64 ISSUES IN THE CONTROL OF EMESIS FUTURE AND RESEARCH Complete elimination of vomiting and nausea ENHANCING EMETIC CONTROL IN PRACTICE Effectiveness = Efficacy THE ROLE AND VALUE OF GUIDELINES Enhancing incorporation of guidelines into practice
65 Multiple roles for supportive care in cancer Reduce or eliminate associated symptoms and side-effects Preserve or improve quality of life Enhance the use of the most effective anti-neoplastic agents Positively affect survival and the quality of that survival Cancer patients are living longer and better lives, thanks to better symptom control, more effective therapies, and a deeper understanding of cancer Dr. Harold Varmus, Director NCI, PBS Newshour, September 24, 2012
66 P. Hetzel, MD
67 Palonosetron Dosing in 8 Studies - Individual Patient Data Meta-analysis: Overall Complete Response TOTAL HEC MEC Grunberg RR= 1.00 (CI 0.83, 1.2) RR= (CI 0.88, 1.641) RR= (CI 0.718, 1.135) Eisenberg-2 Oral HEC Gralla Eisenberg Aapro Masuda Tabei Favors 0.25 mg Odds Ratio Favors 0.75 mg References: Lesser et al, Proc IASLC 2009; Raftopoulos et al, Proc ASCO 2009
Why Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationOverview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationANTIEMETICS and FEBRILE NEUTROPENIA. Matti S. Aapro Genolier Switzerland
ANTIEMETICS and FEBRILE NEUTROPENIA Matti S. Aapro Genolier Switzerland 2010 Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide. Disclosures Collaborations in this
More informationPERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER
June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, onceper-cycle treatment for the prevention
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationDavid G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,
r e v i e w Best Practice Management of CINV in Oncology Patients: I. Physiology and Treatment of CINV Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches David
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationOriginal. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis
Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationOrganizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD
PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 Organizing and Overall Meeting
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationIntroduction ORIGINAL ARTICLE. Paul J. Hesketh 1 & Marco Palmas 2 & Pierre Nicolas 3
Support Care Cancer (18) 26:1151 1159 https://doi.org/.7/s5-17-3936-9 ORIGINAL ARTICLE Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of (netupitant-palonosetron),
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationClass Update with New Drug Evaluation: Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationDrug Class Literature Scan: Newer Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMINI-REVIEW. Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy
MINI-REVIEW Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy Shi-Yong Wang 1 *, Zhen-Jun Yang 2, Zhe Zhang 1, Hui Zhang 1 Abstract Chemotherapy is a major
More informationSafety, efficacy, and patient acceptability of singledose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
Patient Preference and Adherence open access to scientific and medical research Open Access Full Text Article Review Safety, efficacy, and patient acceptability of singledose fosaprepitant regimen for
More informationHIGHLIGHTS ESMO 2017 SUPPORTIVE AND PALLIATIVE CARE
HIGHLIGHTS ESMO 2017 SUPPORTIVE AND PALLIATIVE CARE Florian Scotté MD-PhD Hôpital Foch, Suresnes, France esmo.org DISCLOSURE SLIDE Consultant / Advisory Boards / Speaker: Tesaro, Sanofi, Roche, MSD, TEVA,
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCDR May Aprepitant Emend Merck Frosst Canada Ltd. Indication Chemotherapy-induced Nausea and Vomiting
Overview of CDR Clinical and Pharmacoeconomic Reports CDR May 2008 Aprepitant Emend Merck Frosst Canada Ltd. Indication Chemotherapy-induced Nausea and Vomiting Cite as: Common Drug Review. Aprepitant
More informationA systemic review and meta analysis of Aprepitant Combination Regimens (ACR) for prevention of Chemotherapy induced Nausea
A systemic review and meta analysis of Aprepitant Combination Regimens (ACR) for prevention of Chemotherapy induced Nausea and Vomiting (CINV) in adults Fahad Zubair, PGY 3 UB CHS Internal Medicine Nausea
More informationCADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report
CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, once-percycle treatment for the prevention
More informationORIGINAL ARTICLE. Ralph Boccia & Steven Grunberg & Edwin Franco-Gonzales & Edward Rubenstein & Daniel Voisin
Support Care Cancer (2013) 21:1453 1460 DOI 10.1007/s00520-012-1691-5 ORIGINAL ARTICLE Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea
More informationReviews on Recent Clinical Trials
Reviews on Recent Clinical Trials Send Orders for Reprints to reprints@benthamscience.ae 193 Reviews on Recent Clinical Trials, 2017, 12, 193-201 REVIEW ARTICLE ISSN: 1574-8871 eissn: 1876-1038 : An NK-1
More informationCME. The faculty reported the following financial relationships or relationships to
CME Target Audience This activity has been designed to meet the educational needs of oncologists, hematologists, and oncology nurses involved in the management of cancer patients receiving chemotherapy.
More informationSupportive Care Select Topics Updated May 2017 by Dr. Charles Lim (PGY-5 Medical Oncology Resident, University of Toronto)
Supportive Care Select Topics Updated May 2017 by Dr. Charles Lim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Warr (Staff Medical Oncologist, University of Toronto) DISCLAIMER:
More informationAn Evidence Practice Gap in Antiemetic Prescription with Chemotherapy
2014 An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy Chepsy C Philip 1*, Biju George 1 1 Department of Clinical Haematology, CMC Vellore, Tamil Nadu, India. ARTICLE INFO Article type:
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology March 2015 New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting Discussants Lee S.
More informationCIC Edizioni Internazionali. Chemotherapy-induced nausea and vomiting: update and future options. Review
Review Chemotherapy-induced nausea and vomiting: update and future options Umberto Pacetti 1 Silvia Ileana Sara Fattoruso 1 Enzo Veltri 2 1 Operative Unit of Oncology, A. Fiorini Hospital, Terracina, Italy
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationAdherence to guidelines on prophylaxis of chemotherapy-induced nausea and vomiting in the National Cancer Institute, Sudan
Southern African Journal of Gynaecological Oncology 2017; 9(2):7-11 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology October 2015 Advances in the Management of Chemotherapy-Induced ausea and Vomiting: ew Data From Recent and Ongoing Trials Discussants
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationCompany Update. November 2015
Company Update November 2015 Legal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEuropean Medicines Agency
European Medicines Agency SCIENTIFIC DISCUSSION 1. Introduction Emend is an oral substance P, aka human neurokinin 1 (NK-1)-receptor antagonist. Mammalian tachykinin substance P (SP) that binds to the
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 6/15/18 Pharmacy- Formulary 1 x Next Review: 6/19 Pharmacy- Formulary 2 x Date of Origin: 4/99 Antiemetic Agents: Zofran /ODT (ondansetron/ondansetron
More informationAvailable online at ScienceDirect. journal homepage:
European Journal of Cancer 57 (2016) 23e30 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Original Research Efficacy and safety of rolapitant for prevention
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationclinical practice guidelines
clinical practice guidelines Annals of Oncology 21 (Supplement 5): v232 v243, 2010 doi:10.1093/annonc/mdq194 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced
More informationDepartment of Medical Oncology. Department of Biostatistics Cancer Institute (WIA), Chennai, India
Intravenous Fosaprepitant for the prevention of chemotherapy induced vomiting in children: a double blind placebo controlled, phase III randomized trial Venkatraman Radhakrishnan 1, Archit Joshi 1, Jaikumar
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationCancer Studies Open Access
Cancer Studies Open Access Received: Sep 16, 2014 Accepted: Oct 10, 2014 Published: Oct 14, 2014 http://dx.doi.org/10.14437/csoa-1-107 Research Hiroshi Ishiguro, Cancer Stud Open Access 2014: 1:2 Prevention
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationRecent Advances and Updated Guidelines in the Management of Chemotherapy-Induced Nausea and Vomiting
N o v e m b e r 2 0 1 1 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 9, I s s u e 1 1, S u p p l e m e n t 2 7 Moderator Discussants Lee S. Schwartzberg, MD, FACP Clinical Oncologist Medical
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More informationChemotherapy-induced nausea and vomiting
Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children Veerendra Patil, MD, FNB; Harsha Prasada, MD, DCH,
More informationEffect of chemotherapy-induced nausea on patients quality of life
Art & science literature review Effect of chemotherapy-induced nausea on patients quality of life Melissa Fitzgerald and Siobhan Murphy discuss ways to manage treatment side effects including non pharmacological
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak @bosnjaksupport Institute for Oncology and Radiology of Serbia Serbia, Belgrade Supportive Care in Cancer The prevention & management
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationReview Article Prophylactic Management of Radiation-Induced Nausea and Vomiting
BioMed Research International Volume 2015, Article ID 893013, 8 pages http://dx.doi.org/10.1155/2015/893013 Review Article Prophylactic Management of Radiation-Induced Nausea and Vomiting Petra Feyer,
More informationNeurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis
JNCI J Natl Cancer Inst (2017) 109(2): djw217 doi: 10.1093/jnci/djw217 First published online October 30, 2016 Article Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced
More information, Gianluca Ballinari. ) receptor antagonist,
Leukemia & Lymphoma, March 2014; 55(3): 544 550 2014 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2013.813498 ORIGINAL ARTICLE: CLINICAL Multicenter phase IV study of
More informationCan Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low- Emetogenic Chemotherapy?
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.469 RESEARCH ARTICLE Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low- Emetogenic Chemotherapy? Chan
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationResearch Article. Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life
Research Article Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life Aim: To compare chemotherapy-induced nausea and vomiting
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationThe MASCC Guidelines Policy
The MASCC Guidelines Policy Recommendations for MASCC Guideline Construction and the Endorsement of Externally Generated Guidelines Preamble MASCC recognizes that providing supportive care facilitates
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationHHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 March 09.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting Rudolph M. Navari, M.D., Rui Qin, Ph.D., Kathryn J. Ruddy, M.D., Heshan Liu, Ph.D., Steven F. Powell, M.D., Madhuri Bajaj, M.D.,
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationMASCC/ESMO ANTIEMETIC GUIDELINE 2016
1 MASCC/ESMO ANTIEMETIC GUIDELINE 2016 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex
More informationPublished Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More informationThe influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting
Journal of BUON 12: 245-252, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting T. Sarcev
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationANTIEMETIC GUIDELINES
ANTIEMETIC GUIDELINES REVISED DECEMBER 2017 These guidelines for adults are a summary of the knowledge updated from initial variant of June 1997. As this is a fluid field regular updates will occur as
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationConsultations. Perspectives on Improving the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting (CINV)
Oncology Consultations Perspectives on Improving the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting (CINV) Developing Clinically and Economically Efficient Antiemetic Regimens A CME-Certified
More informationDrug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting
Texas Vendor Drug Program Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting Publication History Developed September 1996. Revised July 2018; September 2016; June 2015;
More information